

# Obesity and kidney disease: hidden consequences of the epidemic



**Obesity is a growing worldwide epidemic. Obesity is one of the strongest risk factors for new-onset chronic kidney disease, and also for nephrolithiasis and for kidney cancer. This year the World Kidney Day promotes education on the harmful consequences of obesity and its association with kidney disease, advocating healthy lifestyle and health policy measures that make preventive behaviors an affordable option.**

*Kidney International* (2017) **91**, 260–262; <http://dx.doi.org/10.1016/j.kint.2016.10.019>  
Copyright © World Kidney Day 2017 Steering Committee

In 2014, over 600 million adults worldwide were obese. Obesity increases the risk of developing major risk factors for chronic kidney disease (CKD), such as diabetes and hypertension, and it has a direct impact on the development of CKD and end-stage renal disease (ESRD). The good news is that obesity is largely preventable. Education and awareness of the risks of obesity and a healthy lifestyle, including proper nutrition and exercise, can dramatically help in preventing obesity and kidney disease. This article reviews the association of obesity with kidney disease on the occasion of the 2017 World Kidney Day.

## ASSOCIATION OF OBESITY WITH CKD AND OTHER RENAL COMPLICATIONS

Numerous studies have shown an association between measures of obesity and both the development and the progression of CKD. In general, the associations between obesity and poorer renal outcomes persist even after adjustments for possible mediators of obesity's cardiovascular and metabolic effects, suggesting that obesity may affect kidney function through mechanisms in part unrelated to these complications. The deleterious effect of obesity on the kidneys extends to other complications such as nephrolithiasis and kidney malignancies.

## MECHANISMS OF ACTION UNDERLYING THE RENAL EFFECTS OF OBESITY

The exact mechanisms whereby obesity may worsen or cause CKD remain unclear. Some of the deleterious renal consequences of obesity may be mediated by comorbid conditions such as diabetes mellitus or hypertension, but there are also effects of adiposity that impact the kidneys directly via production of (among others) adiponectin, leptin, and resistin (Figure 1). These include the development of inflammation, oxidative stress, abnormal

lipid metabolism, activation of the renin-angiotensin-aldosterone system, and increased production of insulin and insulin resistance.<sup>1</sup>

These various effects result in pathologic changes in the kidneys including ectopic lipid accumulation and increased deposition of renal sinus fat, glomerular hypertension, and increased glomerular permeability, and, ultimately, the development of glomerulomegaly and focal or segmental glomerulosclerosis (Figure 2).<sup>2</sup> The incidence of the so-called obesity-related glomerulopathy has increased 10-fold between 1986 and 2000.

Obesity is associated with a number of risk factors contributing to nephrolithiasis, such as lower urine pH and increased urinary oxalate, uric acid, sodium, and phosphate excretion. The insulin resistance characteristic of obesity also may predispose to nephrolithiasis through its impact on the tubular Na-H exchanger and ammoniogenesis, and the promotion of an acidic milieu.<sup>3</sup>

The putative mechanisms behind the increased risk of kidney cancers observed in obese individuals include insulin resistance, chronic hyperinsulinemia, and increased production of insulin-like growth factor 1, which may exert stimulating effects on the growth of various types of tumor cells. More recently, the endocrine functions of adipose tissue, its effects on immunity, and the generation of an inflammatory milieu with complex effects on cancers have emerged as additional explanations.<sup>4</sup>

## OBESITY IN PATIENTS WITH ADVANCED KIDNEY DISEASE: THE NEED FOR A NUANCED APPROACH

In a seemingly counterintuitive manner, obesity has been associated consistently with lower mortality rates in patients with CKD and ESRD.<sup>5</sup> It is possible that the seemingly protective effect of a high body mass index is the

Csaba P. Kovcsdy<sup>1,2</sup>, Susan L. Furth<sup>3</sup> and Carmine Zoccali<sup>4</sup>; for the World Kidney Day Steering Committee<sup>5</sup>


<sup>1</sup>Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA; <sup>2</sup>Nephrology Section, Memphis VA Medical Center, Memphis, Tennessee, USA; <sup>3</sup>Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA; and <sup>4</sup>National Research Council-Institute Of Clinical Physiology Clinical Epidemiology and Pathophysiology of Renal Diseases and Hypertension, Reggio Calabria, Italy

**Correspondence:** World Kidney Day, International Society of Nephrology, in collaboration with International Federation of Kidney Foundation, Rue de Fabriques 1B, 1000, Brussels, Belgium.

E-mail: [myriam@worldkidneyday.org](mailto:myriam@worldkidneyday.org)

<sup>5</sup>See Appendix for list of committee members.

This article is being published in *Kidney International* and reprinted concurrently in several journals. The articles are identical except for minor stylistic and spelling changes in keeping with each journal's style. Any of these versions may be used in citing this article.




**Figure 1 | Putative mechanisms of action whereby obesity causes chronic kidney disease.** CKD, chronic kidney disease; CVD, cardiovascular disease; DM, diabetes mellitus; HTN, hypertension; RAAS, renin-angiotensin-aldosterone system.

result of the imperfection of body mass index as a measure of obesity. However, there is also evidence to suggest that higher adiposity, especially subcutaneous (nonvisceral) fat, also may be associated with better outcomes in ESRD patients. Such benefits may be present in patients who have very low short-term life expectancy, such as most ESRD patients; including, among others, benefits from better nutritional status.

**POTENTIAL INTERVENTIONS FOR MANAGEMENT OF OBESITY**

**Countering CKD at a population level**

In the United States, Healthy People 2020, a program that sets 10-year health targets for



**Figure 2 | Obesity-related perihilar focal segmental glomerulosclerosis on a background of glomerulomegaly.** Periodic acid–Schiff stain, original magnification ×400. Figure courtesy of Dr. Patrick D. Walker, MD (Arkana Laboratories, Little Rock, AR).

health promotion and prevention goals, focuses both on CKD and obesity. A successful surveillance system for CKD already has been implemented in some places such as the United Kingdom,<sup>6</sup> which may serve as a platform to improve the prevention of obesity-related CKD. Campaigns aiming to reduce the obesity burden are now at center stage worldwide and strongly are recommended by the World Health Organization and it is expected that these campaigns will reduce the incidence of obesity-related complications, including CKD.

**Prevention of CKD progression in obese people with CKD**

Obesity-related goals in obese CKD patients remain vaguely formulated, largely because of the paucity of high-level evidence intervention studies to modify obesity in CKD patients. In overweight or obese diabetic patients, a lifestyle intervention including caloric restriction and increased physical activity compared with a standard follow-up evaluation reduced the risk for incident CKD by 30%.<sup>7</sup> In a recent meta-analysis collating experimental studies in obese CKD patients, interventions aimed at reducing body weight showed coherent reductions in blood pressure, glomerular hyperfiltration, and proteinuria.<sup>8</sup> Bariatric surgical intervention has been suggested for selected CKD and ESRD patients.

Globally, these experimental findings provide a proof of concept for the usefulness of weight reduction and angiotensin-converting enzyme inhibition interventions in the treatment of CKD in the obese population. Studies showing a survival benefit of increased body mass index in CKD patients, however, remain to be explained. These findings limit our ability to make strong recommendations about the usefulness and the safety of weight reduction among individuals with more advanced stages of CKD. Lifestyle recommendations to reduce body weight in obese people at risk for CKD and in those with early CKD appear justified, particularly recommendations for the control of diabetes and hypertension.

**CONCLUSIONS**

The worldwide epidemic of obesity affects the Earth’s population in many ways. Diseases of the kidneys, including CKD, nephrolithiasis, and kidney cancers, are among the more insidious effects of obesity, but nonetheless have wide-ranging deleterious consequences, ultimately leading to significant excess morbidity and

mortality and excess costs to individuals and the entire society. Population-wide interventions to control obesity could have beneficial effects in preventing the development, or delaying the progression, of CKD. It is incumbent on the entire health care community to devise long-ranging strategies toward improving the understanding of the links between obesity and kidney diseases, and to determine optimal strategies to stem the tide. The 2017 World Kidney Day is an important opportunity to increase education and awareness to that end.

**DISCLOSURE**

All the authors declared no competing interests.

**REFERENCES**

1. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. *Eur Cytokine Netw.* 2006;17:4–12.
2. de Vries AP, Ruggenti P, Ruan XZ, et al. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. *Lancet Diabetes Endocrinol.* 2014;2:417–426.

3. Daudon M, Lacour B, Jungers P. Influence of body size on urinary stone composition in men and women. *Urol Res.* 2006;34:193–199.
4. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. *Nat Rev Cancer.* 2004;4:579–591.
5. Lu JL, Kalantar-Zadeh K, Ma JZ, et al. Association of body mass index with outcomes in patients with CKD. *J Am Soc Nephrol.* 2014;25:2088–2096.
6. O'Donoghue DJ, Stevens PE. A decade after the KDOQI CKD/guidelines: a perspective from the United Kingdom. *Am J Kidney Dis.* 2012;60:740–742.
7. Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. *N Engl J Med.* 2013;369:145–154.
8. Bolignano D, Zoccali C. Effects of weight loss on renal function in obese CKD patients: a systematic review. *Nephrol Dial Transplant.* 2013;28(suppl 4):iv82–iv98.

**APPENDIX**

Members of the World Kidney Day Steering Committee are Philip Kam Tao Li, Guillermo Garcia-Garcia, Mohammed Benghanem-Gharbi, Rik Bollaert, Sophie Dupuis, Timur Erk, Kamyar Kalantar-Zadeh, Csaba Kovesdy, Charlotte Osafo, Miguel C. Riella, and Elena Zakharova.